AR113227A1 - Compuestos y composiciones para inducir condrogénesis - Google Patents
Compuestos y composiciones para inducir condrogénesisInfo
- Publication number
- AR113227A1 AR113227A1 ARP180101514A ARP180101514A AR113227A1 AR 113227 A1 AR113227 A1 AR 113227A1 AR P180101514 A ARP180101514 A AR P180101514A AR P180101514 A ARP180101514 A AR P180101514A AR 113227 A1 AR113227 A1 AR 113227A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- substituted
- hydrogen
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000022159 cartilage development Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable, o estereoisómero del mismo compuesto; caracterizado porque R⁰ es hidrógeno o alquilo C₁₋₆; R² es fenilo; un heteroarilo de 5 ó 6 miembros o un heterociclilo de 5 ó 6 miembros, teniendo cada uno de 1 a 3 heteroátomos seleccionados entre N, O y S; en donde R² es sustituido o no sustituido con 1 a 3 sustituyentes seleccionados independientemente de halo, alquilo C₁₋₆ sustituido con halo, alquilo C₁₋₆, alcoxilo C₁₋₆ sustituido con halo, alcoxilo C₁₋₆, ciano, alquilsulfonilo C₁₋₆, fenilo sustituido o no sustituido con halo o alquilo C₁₋₆; R³ es un heteroarilo de 5 ó 6 miembros que tiene de 1 a 2 heteroátomos seleccionados entre N, O y S; en donde R³ es sustituido o no sustituido con 1 a 3 sustituyentes seleccionados independientemente entre halo, alquilo C₁₋₆, alquilo C₁₋₆ sustituido con halo, alcoxilo C₁₋₆ o -NR⁵R⁶; R¹ᵃ, R¹ᵇ, R⁴ᵃ, y R⁴ᵇ son cada uno independientemente hidrógeno, halo, hidroxilo, alcoxilo C₁₋₆, alquilo C₁₋₆, -NR⁷R⁸ o -NR⁷-(CR⁹R¹⁰)₂₋₄-OR¹¹; o en donde uno de R¹ᵃ y R¹ᵇ junto con uno de R⁴ᵃ y R⁴ᵇ forman un ciclopropilo con los dos átomos de carbono a los que dichos R¹ᵃ, R¹ᵇ, R⁴ᵃ y R⁴ᵇ están unidos respectivamente; R⁵, R⁶, R⁷, R⁹, R¹⁰ y R¹¹ son cada uno independientemente hidrógeno o alquilo C₁₋₆; R⁸ es hidrógeno, cicloalquilo C₃₋₇ o un heterociclilo de 5 ó 6 miembros que tiene 1 - 3 heteroátomos seleccionados entre N, O y S; donde dicho cicloalquilo C₃₋₇ o heterociclilo de 5 ó 6 miembros de R⁸ es sustituido o no sustituido con hidroxilo o alquilo C₁₋₆; alternativamente, R⁵ y R⁶ o R⁷ y R⁸ junto con el átomo de nitrógeno al que están unidos en -NR⁵R⁶ o -NR⁷R⁸ respectivamente forman un heterociclilo de 5 ó 6 miembros que tiene 1 - 3 heteroátomos seleccionados entre N, O y S; siempre que R¹ᵃ, R¹ᵇ, R⁴ᵃ y R⁴ᵇ no puedan ser todos hidrógeno; y además, considerando que siempre que R¹ᵃ, R¹ᵇ, R⁴ᵃ o R⁴ᵇ sea un alquilo C₁₋₆, el otro sustituyente en el mismo átomo del anillo de carbono no sea hidrógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517394P | 2017-06-09 | 2017-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113227A1 true AR113227A1 (es) | 2020-02-19 |
Family
ID=62837959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101514A AR113227A1 (es) | 2017-06-09 | 2018-06-06 | Compuestos y composiciones para inducir condrogénesis |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US11091499B2 (es) |
| EP (3) | EP3634967A1 (es) |
| JP (2) | JP7229945B2 (es) |
| KR (1) | KR102656524B1 (es) |
| CN (1) | CN110719913B (es) |
| AR (1) | AR113227A1 (es) |
| AU (1) | AU2018279306C1 (es) |
| BR (1) | BR112019025866A2 (es) |
| CA (1) | CA3063985A1 (es) |
| CL (1) | CL2019003564A1 (es) |
| CO (1) | CO2019013706A2 (es) |
| CR (1) | CR20190551A (es) |
| CU (1) | CU24577B1 (es) |
| DK (1) | DK3915994T3 (es) |
| DO (1) | DOP2019000305A (es) |
| EA (1) | EA201992858A1 (es) |
| EC (1) | ECSP19086712A (es) |
| FI (1) | FI3915994T3 (es) |
| HR (1) | HRP20240155T1 (es) |
| IL (2) | IL300755A (es) |
| JO (1) | JOP20190282A1 (es) |
| LT (1) | LT3915994T (es) |
| MA (2) | MA57022B1 (es) |
| MX (1) | MX2019014757A (es) |
| NZ (1) | NZ759434A (es) |
| PE (1) | PE20200403A1 (es) |
| PH (1) | PH12019502764A1 (es) |
| PT (1) | PT3915994T (es) |
| RS (1) | RS65161B1 (es) |
| SA (1) | SA519410729B1 (es) |
| SI (1) | SI3915994T1 (es) |
| TW (1) | TWI782036B (es) |
| UY (1) | UY37759A (es) |
| WO (1) | WO2018225009A1 (es) |
| ZA (1) | ZA201907358B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190282A1 (ar) * | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
| CN113015735A (zh) * | 2018-12-06 | 2021-06-22 | 诺华股份有限公司 | 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物 |
| EP3891155B1 (en) * | 2018-12-06 | 2023-08-30 | Novartis AG | 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| ECSP982358A (es) | 1998-01-06 | 1998-12-22 | Derivados ciclicos de sulfona | |
| US6407250B1 (en) | 2000-09-14 | 2002-06-18 | Allergan Sales, Inc. | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists |
| US6369089B1 (en) | 2000-09-14 | 2002-04-09 | Allergan Sales, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| CN1213050C (zh) | 2000-11-23 | 2005-08-03 | 拜尔公司 | 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途 |
| US6653468B1 (en) | 2002-07-31 | 2003-11-25 | Isis Pharmaceuticals, Inc. | Universal support media for synthesis of oligomeric compounds |
| JP2005068052A (ja) | 2003-08-22 | 2005-03-17 | Mitsui Chemicals Inc | 新規なフラン誘導体及びその製造方法 |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| US7595327B2 (en) * | 2005-03-21 | 2009-09-29 | Wyeth | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase |
| WO2008008884A2 (en) | 2006-07-12 | 2008-01-17 | Cornell Research Foundation, Inc. | Inhibition of beta-amyloid peptide aggregation |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| EP2414367B1 (en) | 2009-04-02 | 2014-08-13 | Allergan, Inc. | Prostaglandin e receptor antagonists |
| MA33423B1 (fr) | 2009-07-14 | 2012-07-03 | Scripps Research Inst | Différentiation de cellules souches mésenchymateuses |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| WO2012177856A2 (en) | 2011-06-21 | 2012-12-27 | Adispell, Inc. | Cognition modification |
| WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| AU2014236719B2 (en) * | 2013-03-15 | 2018-06-21 | The California Institute For Biomedical Research | Compounds and methods for inducing chondrogenesis |
| MY186570A (en) * | 2014-05-13 | 2021-07-27 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
| JP2016204316A (ja) | 2015-04-24 | 2016-12-08 | 日東電工株式会社 | 核酸固相合成用リンカー及び担体 |
| JOP20190282A1 (ar) | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
-
2017
- 2017-06-16 JO JOP/2019/0282A patent/JOP20190282A1/ar unknown
-
2018
- 2018-06-05 UY UY0001037759A patent/UY37759A/es unknown
- 2018-06-06 AR ARP180101514A patent/AR113227A1/es unknown
- 2018-06-07 CN CN201880037287.1A patent/CN110719913B/zh active Active
- 2018-06-07 CR CR20190551A patent/CR20190551A/es unknown
- 2018-06-07 TW TW107119618A patent/TWI782036B/zh active
- 2018-06-07 BR BR112019025866-3A patent/BR112019025866A2/pt unknown
- 2018-06-07 AU AU2018279306A patent/AU2018279306C1/en active Active
- 2018-06-07 DK DK21178695.9T patent/DK3915994T3/da active
- 2018-06-07 CU CU2019000098A patent/CU24577B1/es unknown
- 2018-06-07 IL IL300755A patent/IL300755A/en unknown
- 2018-06-07 RS RS20240179A patent/RS65161B1/sr unknown
- 2018-06-07 PE PE2019002520A patent/PE20200403A1/es unknown
- 2018-06-07 PT PT211786959T patent/PT3915994T/pt unknown
- 2018-06-07 NZ NZ759434A patent/NZ759434A/en unknown
- 2018-06-07 EP EP18737718.9A patent/EP3634967A1/en not_active Withdrawn
- 2018-06-07 EP EP23203447.0A patent/EP4299123A3/en active Pending
- 2018-06-07 EP EP21178695.9A patent/EP3915994B9/en active Active
- 2018-06-07 MA MA57022A patent/MA57022B1/fr unknown
- 2018-06-07 FI FIEP21178695.9T patent/FI3915994T3/fi active
- 2018-06-07 MA MA050547A patent/MA50547A/fr unknown
- 2018-06-07 HR HRP20240155TT patent/HRP20240155T1/hr unknown
- 2018-06-07 MX MX2019014757A patent/MX2019014757A/es unknown
- 2018-06-07 EA EA201992858A patent/EA201992858A1/ru unknown
- 2018-06-07 LT LTEP21178695.9T patent/LT3915994T/lt unknown
- 2018-06-07 US US16/620,407 patent/US11091499B2/en active Active
- 2018-06-07 WO PCT/IB2018/054123 patent/WO2018225009A1/en active Application Filing
- 2018-06-07 SI SI201831061T patent/SI3915994T1/sl unknown
- 2018-06-07 CA CA3063985A patent/CA3063985A1/en active Pending
- 2018-06-07 JP JP2019567650A patent/JP7229945B2/ja active Active
- 2018-06-07 KR KR1020207000290A patent/KR102656524B1/ko active IP Right Grant
-
2019
- 2019-11-06 ZA ZA2019/07358A patent/ZA201907358B/en unknown
- 2019-12-03 IL IL271154A patent/IL271154B2/en unknown
- 2019-12-05 CO CONC2019/0013706A patent/CO2019013706A2/es unknown
- 2019-12-05 DO DO2019000305A patent/DOP2019000305A/es unknown
- 2019-12-05 CL CL2019003564A patent/CL2019003564A1/es unknown
- 2019-12-05 EC ECSENADI201986712A patent/ECSP19086712A/es unknown
- 2019-12-05 SA SA519410729A patent/SA519410729B1/ar unknown
- 2019-12-06 PH PH12019502764A patent/PH12019502764A1/en unknown
-
2021
- 2021-07-06 US US17/368,537 patent/US11753416B2/en active Active
-
2023
- 2023-02-15 JP JP2023021335A patent/JP7432778B2/ja active Active
- 2023-07-18 US US18/354,163 patent/US20230365580A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112529A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| AR106948A1 (es) | Agonistas del receptor de apelina y método de uso | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR094929A1 (es) | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 | |
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR097279A1 (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx | |
| AR113227A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR104415A1 (es) | Compuestos antiestrogénicos derivados de cromeno | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR102972A1 (es) | Compuestos de dihidropirimidin-2-ona y su uso médico | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina |